News ArchiveNewsarchiv
    Home
    t2cure’s cell therapy is available through cooperating clinical centres
    t2cure cooperates with experienced partners in research and in the industry.
    t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
    t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.

    News Archive

    miRagen Therapeutics and t2cure Sign Licensing Agreement for microRNA Target Implicated in Vascular Disease11.30.2010

    + Read more

    t2cure’s Cellular Therapeutic Receives Orphan Drug Designation 06.24.2010

    + Read more

    t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA05.25.2010

    FRANKFURT, May 25, 2010 /PRNewswire/ -- t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the quality of its lead product t2c001 has been certified by the...

    + Read more

    Stem Cell Company t2cure Appoints Dr Petra Rueck and Susanne Knigge as Co-CEOs01.11.2010

    + Read more

    t2cure to present at Science4Life fair10.16.2009

    + Read more